Merck (ETR:MRK) May Have Just Reached An Inflection Point; Deutsche Bank AG Upgrades Shares


Merck (ETR:MRK) Stock Upgrade

In an interesting research report shared with investors and clients on Saturday, 28 November, Deutsche Bank AG has upgraded shares of Merck (ETR:MRK) stock to a solid Buy and has published an estimated 12-month target PPS to EUR 108.00. This target is 12.08% from MRK’s current share price.

From a total of 14 analysts covering Merck (ETR:MRK) stock, 7 rate it a ”Buy”, 2 a “Sell”, and 5 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is €115 while the lowest target price is €75. The mean of all analyst targets is €97.32 with a 0.96% above today’s (€96.39) stock price. Merck was the topic of 23 analyst reports since August 4, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank upgraded shares on November 28 to “Buy” rating. Baader Wertpapierhandelsbank maintained shares with “Hold” rating and €96 target share price in a report from an October 15. S&P Research maintained MRK stock in a recent report from November 13 with “Hold” rating. Commerzbank upgraded the rating on October 3. Commerzbank has a “Buy” rating and a €105 price target on shares. Finally, BNP Paribas upgraded the stock to “Outperform” rating in a report issued on an October 22.

The stock decreased 0.07% or EUR 0.07 on November 27, striking EUR 96.39. Approximately 376,471 shares of stock traded hands. Merck KGaA (ETR:MRK) has declined 5.50% since April 27, 2015 and is downtrending. It has underperformed by 4.61% the S&P500.

 Merck (ETR:MRK) May Have Just Reached An Inflection Point; Deutsche Bank AG Upgrades Shares

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The company has a market cap of 12.46 billion EUR. The Firm diversifies its activities into four business divisions: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. It has 33.02 P/E ratio. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnological origin.

According to Zacks Investment Research, “Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.” Get a free copy of the Zacks research report on Merck KGaA (MRK)